MBIO - Mustang Bio gains after impressing with ASH presentation

Mustang Bio (MBIO) is on watch after Oppenheimer tips on an "excellent clinical profile" for MB-106 at the ASH conference."The poster presentation included results for nine efficacy-evaluable NHL patients—including five who were not in the published ASH abstract. MB-106 delivered impressive activity, achieving an ORR of 89% (4 CRs, 4 PRs), while maintaining a safety profile that we see as favorable relative to currently available CD19 CAR-Ts. Although MB-106 faces an extremely crowded competitive landscape, CD20-directed cell therapy could provide an important lifeline to r/r certain NHL patients, especially those who have failed prior CD19-directed therapy. Mustang expects to file an IND for a registration-oriented multicenter Phase 1/2 trial of MB-106 in 1Q21."The firm keeps an Outperform rating on MBIO.See details on Mustang's ASH presentation.

For further details see:

Mustang Bio gains after impressing with ASH presentation